These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17711855)

  • 1. Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12.
    Cantin L; Faucher F; Couture JF; de Jésus-Tran KP; Legrand P; Ciobanu LC; Fréchette Y; Labrecque R; Singh SM; Labrie F; Breton R
    J Biol Chem; 2007 Oct; 282(42):30910-9. PubMed ID: 17711855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity.
    Pereira de Jésus-Tran K; Côté PL; Cantin L; Blanchet J; Labrie F; Breton R
    Protein Sci; 2006 May; 15(5):987-99. PubMed ID: 16641486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.
    Bohl CE; Wu Z; Miller DD; Bell CE; Dalton JT
    J Biol Chem; 2007 May; 282(18):13648-55. PubMed ID: 17311914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
    Fuse H; Korenaga S; Sakari M; Hiyama T; Ito T; Kimura K; Kato S
    Prostate; 2007 May; 67(6):630-7. PubMed ID: 17342748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide antagonist of the androgen receptor.
    Gao W
    Curr Pharm Des; 2010; 16(9):1106-13. PubMed ID: 20030610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
    Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
    Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimineralocorticoid 11beta-substituted spirolactones exhibit androgen receptor agonistic activity: a structure function study.
    Nirdé P; Térouanne B; Gallais N; Sultan C; Auzou G
    Mol Pharmacol; 2001 May; 59(5):1307-13. PubMed ID: 11306716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Diversity of Ligand-Binding Androgen Receptors Revealed by Microsecond Long Molecular Dynamics Simulations and Enhanced Sampling.
    Duan M; Liu N; Zhou W; Li D; Yang M; Hou T
    J Chem Theory Comput; 2016 Sep; 12(9):4611-9. PubMed ID: 27560203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor antagonists (antiandrogens): structure-activity relationships.
    Singh SM; Gauthier S; Labrie F
    Curr Med Chem; 2000 Feb; 7(2):211-47. PubMed ID: 10637363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamic acid 709 substitutions highlight the importance of the interaction between androgen receptor helices H3 and H12 for androgen and antiandrogen actions.
    Georget V; Bourguet W; Lumbroso S; Makni S; Sultan C; Nicolas JC
    Mol Endocrinol; 2006 Apr; 20(4):724-34. PubMed ID: 16373394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of the androgen receptor at amino acid 708 (Gly-->Ala) abolishes partial agonist activity of steroidal antiandrogens.
    Terouanne B; Nirdé P; Rabenoelina F; Bourguet W; Sultan C; Auzou G
    Mol Pharmacol; 2003 Apr; 63(4):791-8. PubMed ID: 12644579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
    Zhou J; Liu B; Geng G; Wu JH
    Proteins; 2010 Feb; 78(3):623-37. PubMed ID: 19787772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
    Gianti E; Zauhar RJ
    J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
    Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in antiandrogens and selective androgen receptor modulators.
    Haendler B; Cleve A
    Mol Cell Endocrinol; 2012 Apr; 352(1-2):79-91. PubMed ID: 21704118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.
    Sack JS; Kish KF; Wang C; Attar RM; Kiefer SE; An Y; Wu GY; Scheffler JE; Salvati ME; Krystek SR; Weinmann R; Einspahr HM
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4904-9. PubMed ID: 11320241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor.
    Bohl CE; Miller DD; Chen J; Bell CE; Dalton JT
    J Biol Chem; 2005 Nov; 280(45):37747-54. PubMed ID: 16129672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
    J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific recognition of androgens by their nuclear receptor. A structure-function study.
    Poujol N; Wurtz JM; Tahiri B; Lumbroso S; Nicolas JC; Moras D; Sultan C
    J Biol Chem; 2000 Aug; 275(31):24022-31. PubMed ID: 10787411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region.
    Wang Q; Lu J; Yong EL
    J Biol Chem; 2001 Mar; 276(10):7493-9. PubMed ID: 11102454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.